I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Mantle Cell Lymphoma

What's new

Sign up or login to unlock the full suite of MEDICALLY features

Jun 1 / Roche and Genentech
Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): updated analys
NP30179 is a Phase I/II trial of glofitamab in patients with heavily pre-treated relapsed or refractory non-Hodgkin Lymphoma. Updated efficacy and safety data for a subgroup of patients with R/R MCL enrolled in NP30179 are reported in this abstract.

Sign up or login to unlock the full suite of MEDICALLY features

Dec 11 / Roche and Genentech
Fixed-Duration Mosun-Pola has Promising Efficacy and a Manageable Safety Profile in Patients with Prior-BTKi Treated Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study
GO40516 is an ongoing Phase Ib/II study of mosunetuzumab in combination with polatuzumab vedotin in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma. The initial safety and efficacy data from a Phase II expansion cohort of patients with R/R mantle cell lymphoma, who have received prior Bruton’s tyrosine kinase inhibitor therapy, are reported.

Sign up or login to unlock the full suite of MEDICALLY features

Dec 10 / Roche and Genentech
GLOBRYTE: A Phase III, Open-label, Multicenter, Randomized Trial Evaluating Glofitamab▼ Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma
GLOBRYTE is a Phase III, open-label, multicenter, randomized, controlled trial of glofitamab▼ monotherapy in patients with relapsed or refractory mantle cell lymphoma, in comparison with an investigator’s choice of rituximab + bendamustine or rituximab + lenalidomide. The trial design and associated methods of the ongoing GLOBRYTE trial are outlined.

Sign up or login to unlock the full suite of MEDICALLY features

Dec 11 / Roche and Genentech
Glofitamab▼ Step-Up Dosing Induces High Response Rates in Pts With R/R MCL, Most of Whom Had Failed Prior BTKi Therapy
Preliminary efficacy and safety data in patients with relapsed/refractory MCL who received step-up dose glofitamab▼ monotherapy with obinutuzumab pretreatment as part of the Phase I/II NP30179 (NCT03075696) trial.

Ask a question or share feedback